dacarbazine / Generic mfg. - LARVOL DELTA

Preservation of gonadal function following chemotherapy protocols with acvd and acvd-BV in adults diagnosed with advanced-stage Hodgkin lymphoma: A single center experience. (ASH 2025) - "ACVD (Adriamycin 25 mg/m², Cyclophosphamide 400 mg/m², Vinblastine 6 mg/m² (max 10 mg) and Dacarbazine 375 mg/m²) is a modified chemotherapy regimen from ABVD given IV on day 1 and day 15 and repeated every 28 days for 6 cycles, replacing bleomycin with low dose cyclophosphamide to further optimize efficacy and reduce pulmonary and gonadal toxicity. Brentuximab vedotin is added to ACVD (ACVD-BV) in those cases of positive PET following 2 cycles of ACVD...Sperm banking was performed for 18/34 (53%) males before starting chemotherapy, and only 3/22 (13.617%) females received leuprorelin (GnRH agonist) during the chemotherapy... This study shows a favorable advantage of ACVD /ACVD-BV chemotherapy in treating advanced-stage HL where majority of cases gained their gonadal functions. However, limitations include retrospective design, missing baseline gonadal function evaluation, particularly semen analyses, and inconsistent hormone level documentation...."

Clinical • Metastases • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

Efficacy and safety of nivolumab-based therapies in first-line and Relapsed/Refractory Hodgkin lymphoma (ASH 2025) - "Combination regimens involving nivolumab with agents such as brentuximab vedotin (BV), AVD (adriamycin, vinblastine, dacarbazine) combination chemotherapy, and novel immunomodulators have shown promising activity. In relapsed or refractory CHL, nivolumab-based regimens are highly effective, producing durable responses and favorable survival outcomes, especially when combined with chemotherapy or antibody-drug conjugates such as BV. Although AEs are more common in multi-agent regimens, the safety profile remains acceptable. Nivolumab's role as a salvage or consolidation therapy is supported, given its relatively lower efficacy in the first-line therapeutic context."

Clinical • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

Precise-HL trial: Personalized reduction of chemotherapy intensity through ctdna evaluation in advanced Hodgkin lymphoma (ASH 2025) - P2 | "First patient was enrolled in February 2025.Patients will receive the combination of nivolumab (240 mg IV), doxorubicin (25 mg/m2 IV), vinblastine (6mg/m2 IV) dacarbazine (375 mg/m2 IV) on days 1 and 15 of 28-day cycles.Blood samples for PhasED-Seq testing at baseline and post cycle 2 will be sent to Foresight Diagnosticsfor rapid processing (estimated turn-around time 10-14 days). Key eligibility criteria include untreated stage 3 or 4 classic Hodgkin lymphoma, age 18+, measurabledisease per Lugano criteria, and adequate marrow, renal, and hepatic function. Key exclusion criteriainclude current or prior autoimmune disease except vitiligo or thyroid disease on stable replacementdoses, active cardiac disease or ejection fraction < 50%, prior malignancies within 2 years, and pregnantor nursing women."

Circulating tumor DNA • IO biomarker • Metastases • Classical Hodgkin Lymphoma • Dermatology • Endocrine Disorders • Heart Failure • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Lymphoma • Vitiligo

Targeted immunotherapy in children, adolescents, and young adults (CAYA) with newly diagnosed classical Hodgkin lymphoma: A single center experience (ASH 2025) - "Ourapproach combines the use of the antibody-drug conjugat,e brentuximab vedotin (Bv), targeting Reed-Sternberg (RS) cells, along with the anti-CD20 antibody rituximab (RTX) and checkpoint inhibitornivolumab (N) targeting the TME, added to risk-adapted chemotherapy in newly diagnosed CAYA cHLpatients. This chemoimmunotherapy approach allows for anthracycline dose reduction and radiationsparing in intermediate and high-risk patients.Our early cHL clinical trial enrolled patients 3-39yr old who received a backbone of brentuximab vedotin,doxorubicin, vinblastine, dacarbazine, and rituximab (Bv-AVD-R) given on Day 1, 2 and Day 15,16 of eachcycle...The addition of immunotherapy to a reduced-intensity chemotherapy backbone is safe, effective and welltolerated. Targeting the HRS cell as well as the TME via the PD1/PD-L1 axis is a promising approach inCAYA with cHL and allows for reduction in both anthracycline and radiation exposure. This is important inlimiting short- and..."

Clinical • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hodgkin Lymphoma • Lymphoma • Mucositis • Neutropenia

Brentuximab vedotin (Bv)+AVD efficacy is influenced by interim PET, age, ECOG performance status and CIRS-g in previously untreated patients with stage IV classical Hodgkin lymphoma: An Italian real-life multicentric study (ASH 2025) - "Introduction: In Italy, Brentuximab vedotin (Bv) with AVD (adriamycin, vinblastine, dacarbazine) receivedapproval for the first-line treatment of stage IV classical Hodgkin lymphoma (cHL) in September 2021,with no upper age restriction. In a real-life population of stage IV adult cHL, the Bv+AVD regimen efficacy on PFS isinfluenced by TTM, interim PET DS4-5 (that also impacted on OS), age, ECOG-PS and CIRS-G. The Frailtyscore appears useful to select who can benefit less from Bv-AVD and could represent a tool to betterstratify patients in the era of novel standards for the first-line therapy of advanced stage cHL."

Clinical • Metastases • Classical Hodgkin Lymphoma • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Infectious Disease • Lymphoma • Neutropenia

Effects of antibiotic prophylaxis in first-line therapy of advanced stage classic Hodgkin lymphoma: An analysis of the GHSG HD21 study (ASH 2025) - "In the GHSG HD21 trial for advanced-stage classic Hodgkin lymphoma (AS-cHL), patients received polychemotherapy regimens (eBEACOPP[bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone] orBrECADD [brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, anddexamethasone]) with a risk to develop febrile neutropenia (FN) and/or infections. This comprehensive analysis of the HD21 trial demonstrates the efficacy of ABP and peg G-CSF in thetreatment of AS-cHL in preventing FN and higher-grade infections. This effect is most pronounced in thefirst cycle and in patients receiving BrECADD. Based on these results, we recommend the use of ABPduring the first cycle of the BrECADD regimen, at least."

Clinical • Metastases • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Neutropenia

Relapsed/Refractory Hodgkin lymphoma after first-line escalated beacopdac: Adverse outcomes are overcome by use of second-line targeted therapy - an international real-world analysis (ASH 2025) - "The eBEACOPDac regimen, which replaces procarbazine with dacarbazine, isfavoured in some countries due to reduced gonadal and hematologic toxicity, with similar survival rates(Santarsieri, Lancet Oncol 2025)...Most patientsreceived conventional combination 2L chemotherapy (chemo, n=55; 76%), with gemcitibine,dexamethasone and cisplatin (GDP) most frequently used (n=48; 67%). 17 patients (24%) received 2Ltargeted agents: pembro-GVD (n=8), BV-DHAC (n=5), BV-nivo (n=2), pembro-ICE (n=1) and BrentuximabVedotin (BV) monotherapy (n=1)... For R/R HL after 1L eBEACOPDac, patients treated with 2L chemo have inferior outcomes compared topatients who relapse after ABVD. This informs our discussions with patients who relapse after 1LeBEACOPDac when consenting to 2L treatment. The use of 2L targeted agents was associated withsubstantially better outcomes, with a 47% difference in 2-yr PFS, which is unlikely to be attributable todifferences in baseline characteristics alone."

Adverse events • Clinical • Real-world • Real-world evidence • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

Nivolumab with doxorubicin, vinblastine, and dacarbazine (NAVD) in older adults with classic Hodgkin lymphoma: Do S1826 results hold up in the real world? (ASH 2025) - "Overall, 15% pts required steroids withresolution of IrAEs in 56% cases, 30% (n=7) pts required continued therapy (levothyroxine in 4 pts,steroids in 3 pts, medical tx for heart failure in 1 pt). In this largest RWS cohort of OAs treated with NAVD we showed comparable response rates, AEs and 1-year survival outcomes to those in the pivotal S1826 trial. Notably, rates of ≥G3 AEs including infections,neuropathy and IrAEs remained low and manageable. Although survival significantly improved withNAVD compared to historical data, outcomes of OAs remained inferior compared to pts <60 yrs."

Clinical • Real-world • Real-world evidence • Cardiovascular • Classical Hodgkin Lymphoma • Congestive Heart Failure • Endocrine Disorders • Febrile Neutropenia • Gastroenterology • Gastrointestinal Disorder • Heart Failure • Hematological Disorders • Hematological Malignancies • Hepatology • Hodgkin Lymphoma • Immunology • Infectious Disease • Inflammatory Arthritis • Lymphoma • Nephrology • Neutropenia • Pneumonia • Renal Disease • Rheumatology • Sarcoidosis

Incidence of severe chemotherapy-associated nausea and vomiting with brentuximab vedotin and AVD in comparison with ABVD using standard anti-emetic prophylaxis (ASH 2025) - "The BV-AVD (brentuximab vedotin-doxorubicin, vinblastine, dacarbazine) regimen for cHL improves overall survival in advanced stagedisease in comparison to ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine), however, thecomparative incidence of CINV with BV-AVD relative to ABVD is not well described...All patientsreceived anti-emetic prophylaxis of palonosetron and dexamethasone with the first cycle of treatment.The median age of diagnosis for the ABVD group (30 years) and the BV-AVD group (34 years) were similar(p=0.48)... We observed a higher incidence of severe nausea in patients with cHL who were treatedwith BV-AVD as compared to ABVD, when receiving the same standard anti-emetic prophylaxis. Patientstreated with BV-AVD also experienced more hospitalizations for CINV, combined hospitalizations or EDvisits for CINV, and significant weight loss due to CINV. The results of this study suggest that patientsreceiving BV-AVD for cHL may benefit from more intensive..."

Chemotherapy-Induced Nausea and Vomiting • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

Low-dose nivolumab combined with AVD chemotherapy (Nivo40-AVD) for advanced stage classic Hodgkin lymphoma (ASH 2025) - P2 | "Recently published SWOG S1826 trial demonstrated high efficacy and low toxicity of first-line nivolumabcombined with adriamycin, vinblastine, dacarbazine (N-AVD) in newly-diagnosed advanced stage classicHodgkin lymphoma (cHL) with the two-year progression-free survival (PFS) of 92%. In patientsachieving only partial metabolic response after 6 cycles (Deauville score ≥ 4) radiation therapy is allowed.The primary endpoint is 2-year PFS. Secondary endpoints include ORR and CR rates, 2-year overallsurvival, and adverse events rate."

IO biomarker • Metastases • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Infectious Disease • Lymphoma

Dose Escalation shows no benefit compared to continuing ABVD in Hodgkin's lymphoma patients with an interim PET deauville score of 4 (ASH 2025) - "However, in resource-limited regions, escalating to BEACOPP can be costly, challenging, and may not be readily available.Moreover, procarbazine is not avaliable in different regions in Latin America, including Brazil, andescalation should use Dacarbazine in this context...The primary endpoint was progression freesurvival and secondary endpoint was complete response (CR) rate after initial therapy. Among 218 newly diagnosed patients with cHL, 31 (14%) were identified with a DS of 4 on iPET.The median age was 29 years (range, 20-74), with 58% female and 64.5% having advanced-stage disease.Initial treatment predominantly consisted of ABVD, except for one patient treated with AVD due toconcerns on pulmonary toxicity of bleomycin... This real-world study demonstrates that escalating treatment to BEACOP-DAC for all patientswith cHL and a DS of 4 did not provide significant benefit regarding treatment response, R/R rates or PFS,as compared to continuing with ABVD/AVD. We..."

Clinical • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

Real-world clinical outcomes with novel agent combination therapies for the frontline treatment of pediatric and adult advanced-stage Hodgkin lymphoma (ASH 2025) - "Introduction:Brentuximab vedotin (BV) and nivolumab (N) have resulted in significant progress in the treatment ofadvanced-stage Hodgkin lymphoma (AS-HL). The SWOG 1826 trial demonstrated a progression-freesurvival (PFS) and safety benefit with frontline N-AVD (doxorubicin, vinblastine, and dacarbazine)compared to BV-AVD; however, real-world data are limited...This large real-world multicenter study demonstrates that response rates and 1-yr survival outcomes withN-AVD and BV-AVD are similar to the published SWOG 1826 trial (N-AVD vs BV-AVD: 1-yr PFS: 94% vs 86%,Herrera et al. 2024). Increased cardiovascular AEs, dose reductions/omissions and neuropathy with BV-AVD indicate better tolerability with N-AVD; however, the higher rate of febrile neutropenia andinfections in comparison to SWOG 1826 in N-AVD pts suggests that growth factor prophylaxis may bebeneficial in select high-risk subgroups."

Clinical • Clinical data • Combination therapy • Metastases • Real-world • Real-world evidence • Cardiovascular • Febrile Neutropenia • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Neutropenia • Pediatrics • Septic Shock • Thrombosis

Interim and end-of-treatment FDG-PET demonstrate limited ability to predict 3-year progression-free survival with nivolumab-AVD in first-line treatment of advanced stage Hodgkin lymphoma: Imaging sub-analysis of Phase 3 S1826 study (ASH 2025) - "Introduction: The primary analysis of the randomized Phase 3 S1826 study in patients (pts) withpreviously untreated, advanced stage Hodgkin lymphoma (HL) showed a marked improvement in 1- and2-year progression-free survival (PFS) with nivolumab, doxorubicin, vinblastine, dacarbazine (Nivo-AVD)compared to brentuximab vedotin (BV)-AVD (Herrera, NEJM, 2024). Like prior studies in advanced stage HL, both iPET and EoT PET showed statisticallysignificant differences in 3-year PFS for PET-neg vs. PET-pos, however EoT PET results were more clinicallysignificant. Importantly, 84% of iPET-pos pts and 68% of EOT PET-pos pts treated with N-AVD remainprogression-free at 3 yrs, suggesting significant limitations of PET Lugano criteria when applied to currenttherapies in HL and emphasizing the need to continue exploring new response assessment tools such asctDNA."

Clinical • FDG PET • Metastases • P3 data • P3 data: top line • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

A real-world analysis of safety and outcomes with first line nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (NAVD) in patients with classic Hodgkin lymphoma (cHL) – a multicenter cohort study (ASH 2025) - "S1826 demonstrated a 1-year progression free survival (PFS) of 94% forNAVD compared to 86% for brentuximab vedotin-AVD, which remained durable at 2 years (Herrera et al,NEJM 2024)...Among all pts, 14.4% (n=45) requiredsystemic steroids at any time (intravenous in 4.1%), 3.2% (n=10) require ongoingsteroids/immunosuppression and 8.3% other therapy for an irAE (n=23 levothyroxine, n=1 hemodialysis,n=1 heart failure tx, n=1 insulin).Among all pts, 265 (85%) had an interim PET-CT after 2-4 cycles...Pts treated with NAVD in a large RWS showed comparable response rates and 1-year survival outcomesto those in the pivotal S1826 trial. Most AEs were similar and grade 1-2, but close monitoring of irAEs isnecessary given the potential long-term toxicity of checkpoint inhibitors and potential for ≥G3 irAEs(7.5%) in this young patient population. Our data supports the use of NAVD for 1L advanced stage cHL."

Clinical • Combination therapy • Real-world • Real-world evidence • Cardiovascular • Classical Hodgkin Lymphoma • Congestive Heart Failure • Diabetes • Endocrine Disorders • Febrile Neutropenia • Gastroenterology • Gastrointestinal Disorder • Heart Failure • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Lymphoma • Metabolic Disorders • Nephrology • Neutropenia • Pancreatitis • Renal Disease • Rheumatology

The influence of age on patient-reported outcomes (PROs) endpoints on the S1826 cross-network Phase III trial of advanced-stage, classic Hodgkin lymphoma (cHL) (ASH 2025) - "We assessed PROs in S1826, a trial showingthat nivolumab plus doxorubicin, vinblastine, and dacarbazine (N+AVD) resulted in longer progression-free survival compared to brentuximab vedotin plus AVD (BV+AVD). Trial results support the feasibility ofserial collection of PROs, as indicated by high response rates, despite participants' advanced stagedisease and broad institutional participation. Future analyses will address the planned 3-year outcomesas well as formal evaluation of missing data."

Clinical • Metastases • P3 data • Patient reported outcomes • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

Clinical prognostication in the SWOG 1826 randomized clinical trial of nivolumab-AVD versus brentuximab-AVD: Performance of the advanced-stage Hodgkin lymphoma international prognostic index (A-HIPI) (ASH 2025) - "The phase 3 randomized SWOG S1826 study, the largest National Clinical Trials Network study of AS cHL,compared nivolumab with doxorubicin, vinblastine, and dacarbazine (N+AVD) with brentuximab vedotinwith doxorubicin, vinblastine, and dacarbazine (BV+AVD) in pts 12 yrs or older with AS newly diagnosedcHL. This refined prediction model, which leverages continuous datavalues, is poised to serve as the new standard for risk stratification for adults with AS cHL. Funding NIH/NCI grant awards U10CA180888, U10CA180819, R01CA262265-04"

Clinical • Metastases • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

Interim PET-adapted de-escalation chemotherapy regimen for advanced stage classical Hodgkin lymphoma using brentuximab vedotin, pembrolizumab, doxorubicin, and dacarbazine: Phase 2 study (ASH 2025) - "Background :Brentuximab vedotin (Bv), Nivolumab (N) and Pembrolizumab (P) have revolutionized the managementof advanced stage classical Hodgkin Lymphoma (AS cHL). PET adapted de-escalation therapy of BvP+AD in AS cHL demonstrated reasonable safety profile andpromising efficacy in frontline setting. All pts achieved de-escalation arm, which represented a 50%reduction in anthracycline and alkylating agent exposure, minimizing chemotherapy in young Hodgkinlymphoma population without compromising efficacy. Longer follow up and larger cohort will be neededto provide more robust evidence."

Metastases • P2 data • Alopecia • Classical Hodgkin Lymphoma • Endocrine Disorders • Febrile Neutropenia • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Lymphoma • Non-Hodgkin’s Lymphoma

Final analysis of the Phase III GHSG HD21 trial: PET-guided brecadd vs. ebeacopp in advanced-stage classical Hodgkin lymphoma (ASH 2025) - P3 | "Introduction The German Hodgkin Study Group (GHSG) HD21 trial for adult patients with newly diagnosed advanced-stage classical Hodgkin lymphoma (AS-cHL) was designed to reduce treatment-related morbidity (TRMB)and improve efficacy by comparing the novel BrECADD regimen (brentuximab vedotin, etoposide,cyclophosphamide, doxorubicin, dacarbazine, dexamethasone) to the standard eBEACOPP protocol.Here, we report the final efficacy and safety including long-term progression-free survival (PFS), overallsurvival (OS), and late toxicity outcomes. While higher baseline lymphoma burden associates with incomplete remission atPET2, the risk for treatment failure seems mitigated through response-adaptation. Taken together, ourresults establish individualized BrECADD as a standard treatment option for adult patients with newlydiagnosed AS-cHL."

Metastases • P3 data • Acute Myelogenous Leukemia • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

3-year follow-up of the S1826 study confirms improved progression-free survival with nivolumab-AVD compared to brentuximab vedotin-AVD in advanced stage classic Hodgkin lymphoma (ASH 2025) - "Introduction: The randomized phase 3 S1826 study demonstrated that, in adolescent and adult patients(pts) with previously untreated advanced stage (AS) classic Hodgkin lymphoma (cHL), PD-1 blockade withnivolumab in combination with doxorubicin, vinblastine, and dacarbazine (N-AVD) prolongedprogression-free survival (PFS) compared with standard brentuximab vedotin (BV) combined with AVD ata median follow-up of 2 years. The benefit of N-AVD compared to BV-AVD in adolescent and adult pts with AS cHL issustained with 3y follow-up, including all pre-specified age, stage, and IPS risk subgroups. This updatedemonstrates the durability of remissions with N-AVD over time without any new safety signals, andenables benchmarking with other modern cHL trials. Follow-up will continue to evaluate for latetoxicities, OS, and PROs."

Metastases • Classical Hodgkin Lymphoma • Genetic Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Skin Cancer • Solid Tumor

Case Report: Nirogacestat therapy induces rapid response in a patient with refractory, life-threatening desmoid tumor. (PubMed, Front Oncol) - "Following early relapse to surgery, the patient sequentially failed treatment with pegylated liposomal doxorubicin (PLD), sorafenib, and a combination of doxorubicin and dacarbazine. Albeit rarely lethal in general, DT can exert life-threatening danger by local infiltration into vital tissue, such as blood vessels. The presented case highlights the novel γ-secretase inhibitor nirogacestat as a highly effective therapy preventing infiltration of the right carotid artery by a remarkably refractory DT."

Journal • Desmoid Tumors • Oncology • Sarcoma • Solid Tumor

Retrospective single-center study comparing the effectiveness of sunitinib and chemotherapy based on alkylating agents in the treatment of metastatic pheochromocytomas/paragangliomas (ESMO Asia 2025) - "Comparative data on the effectiveness of these options are lacking, which is the purpose of this study. This retrospective single-center study included patients (pts) over 18 years of age who received alkylating agents-based ChT (dacarbazine or temozolomide) or sunitinib (SUN) +/- somatostatin analogues (SA) for metastatic PC/PG from September 2015 to January 2025. The study included 46 pts, 23 in each group. Sunitinib and chemotherapy based on alkylating agents demonstrate comparable efficacy in the treatment of metastatic PC/PG. The choice of therapy should be based on the safety profile of the drug."

Metastases • Retrospective data • Endocrine Cancer • Neuroendocrine Carcinoma • Neuroendocrine Tumor • Oncology • Solid Tumor • SDHB

Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment (clinicaltrials.gov) - P2 | N=23 | Not yet recruiting | Sponsor: City of Hope Medical Center

New P2 trial • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Pulmonary metastasis from adult-type granulosa cell tumor of the testis: a rare case report and literature review. (PubMed, Curr Med Res Opin) - "Second-line treatment with tislelizumab, nab-paclitaxel, carboplatin, and anlotinib led to temporary stabilization. Salvage chemotherapy with doxorubicin, ifosfamide, and dacarbazine failed, and the patient died two months later...Patients who undergo complete resection of metastatic lesions tend to achieve better outcomes, whereas responses to systemic therapy are generally poor. Early identification of high-risk features and consideration of retroperitoneal lymph node dissection may improve prognosis in selected patients."

Journal • Lung Cancer • Oncology • Testicular Cancer • FOXL2

Relapsed Classical Hodgkin Lymphoma in Pregnancy in Two Patients Managed With a Multidisciplinary Approach. (PubMed, Case Rep Oncol Med) - "The first patient with Stage IIIB cHL achieved a complete response (CR) with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) prior to pregnancy but relapsed at 10 weeks of gestation. After delivery, both patients underwent ICE (ifosfamide, carboplatin, and etoposide), followed by consolidation with autologous hematopoietic cell transplantation (auto-HCT). These cases highlight the balance needed to maintain control of disease to allow a safe and uneventful pregnancy."

Journal • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • Transplantation

Nivo40-AVD for Advanced Classic Hodgkin Lymphoma (clinicaltrials.gov) - P2 | N=54 | Recruiting | Sponsor: National Medical Research Radiological Centre of the Ministry of Health of Russia | Trial completion date: Jan 2032 ➔ Jan 2029 | Trial primary completion date: Jan 2029 ➔ Jan 2028

Trial completion date • Trial primary completion date • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology